Protein Kinase Inhibitors: all 15,766 studies that test it

Page 146 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal CancerCompletedNCT00593060Phase 1
• Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic CancerTerminatedNCT00593008Phase 1
• Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsCompletedNCT00591383Phase 1
• Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine TumorsCompletedNCT00590343Phase 2
• Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisCompletedNCT00586651Phase 2
• BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)CompletedNCT00586443Phase 1
• Interaction Study of Rapamycin and Sunitinib in Patients With Advanced CancersCompletedNCT00583063Early Phase 1
• Erlotinib and Sunitinib in NSCLCCompletedNCT00581789Phase 1
• Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male SubjectsCompletedNCT00578916Phase 1
• SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialCompletedNCT00578526Phase 2
• Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00575393Phase 1
• Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate CancerCompletedNCT00574769Phase 1/2
• Erlotinib and Everolimus in Treating Patients With Metastatic Breast CancerCompletedNCT00574366Phase 1
• Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsTerminatedNCT00573404Phase 1
• Low-Dose Oral Imatinib for Scleroderma Pulmonary InvolvementStatus unknownNCT00573326Phase 2
• Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative ColitisCompletedNCT00572585Phase 2
• Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid TumorsCompletedNCT00572078Phase 1
• A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00571675Phase 2
• A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibCompletedNCT00570635Phase 2
• The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic SyndromeWithdrawnNCT00570375Phase 2
• A Study of GW856553X For the Treatment of DepressionTerminatedNCT00569062Phase 2
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid TumorsCompletedNCT00569036Phase 1
• Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)Status unknownNCT00568841Phase 2
• Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT00568750Phase 2
• Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerCompletedNCT00567554Phase 3
• Erlotinib in Treating Patients With Barrett EsophagusStatus unknownNCT00566800Phase 1
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegCompletedNCT00565968Phase 1
• Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic CancerCompletedNCT00565487Phase 1
• Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by SurgeryCompletedNCT00563823Phase 2
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1
• Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and DoxorubicinCompletedNCT00562913Phase 1
• Sorafenib/Docetaxel Dose Escalation TrialCompletedNCT00562523Phase 1
• An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction CancerTerminatedNCT00561197Phase 1/2
• Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and GemcitabineCompletedNCT00560963Phase 1/2
• A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid TumorsTerminatedNCT00560716Phase 1
• A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)CompletedNCT00559182Phase 1
• Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia PatientsTerminatedNCT00558961Phase 1/2
• A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT00558207Phase 2
• Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 2
• Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant PatientsWithdrawnNCT00556257Phase 2
• Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell CarcinomaWithdrawnNCT00556205Phase 2
• 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant PatientsTerminatedNCT00555789Phase 2
• Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based ImmunosuppressionCompletedNCT00555373Not applicable
• A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00555256Phase 1
• WBRT & Erlotinib in Advanced NSCLC and Brain MetastasesTerminatedNCT00554775Phase 2
• Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan CriteriaStatus unknownNCT00554125Phase 3
• Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes MellitusCompletedNCT00552227Phase 1
• A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor PatientsCompletedNCT00551850Phase 1
• Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid TumorsCompletedNCT00551512Phase 1
• A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant MesotheliomaStatus unknownNCT00551252Phase 2
• Gemcitabine/Capecitabine/ZD6474 in Advanced Solid TumorsCompletedNCT00551096Phase 1
• Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic CancerCompletedNCT00550927Phase 1
• Sutent Maintenance After Response to TaxotereStatus unknownNCT00550810Phase 2
• Study Evaluating Oral Administrations of HKI-272 in Healthy Male SubjectsCompletedNCT00550212Phase 1
• A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy MenCompletedNCT00549653Phase 1
• Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerCompletedNCT00548899Phase 2
• Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerWithdrawnNCT00547443Phase 1/2
• Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaWithdrawnNCT00547404Phase 1
• Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate CancerStatus unknownNCT00546039Phase 2
• Pharmacokinetic Study of AEB071 in Patients Following Liver TransplantationCompletedNCT00545259Phase 1
• Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid LeukemiaStatus unknownNCT00544999Phase 1
• A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung CancerCompletedNCT00544960Phase 2
• Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00544804Phase 1
• Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative IntentCompletedNCT00544609Phase 1
• R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung CancerCompletedNCT00544596Phase 1
• Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal CancerCompletedNCT00543842Phase 1
• German Preoperative Adriamycin Docetaxel StudyCompletedNCT00543829Phase 2
• Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
• Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung CancerTerminatedNCT00543335Phase 1
• Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorCompletedNCT00543049Phase 2
• A Study of ARRY-371797 in Subjects Undergoing Third Molar ExtractionCompletedNCT00542035Phase 2
• Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue SarcomaStatus unknownNCT00541840Phase 1/2
• Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord TumorsCompletedNCT00541138Phase 2
• Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerStatus unknownNCT00541021Phase 3
• Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell CancerCompletedNCT00541008Phase 2
• Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal CancerCompletedNCT00540943Phase 1
• Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type PsoriasisCompletedNCT00539929Phase 2
• Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer PatientsTerminatedNCT00539331Phase 1
• Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast CancerStatus unknownNCT00538330Not applicable
• Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)CompletedNCT00538239Phase 3
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00538109Not applicable
• Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant MelanomaStatus unknownNCT00538005Phase 1/2
• Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung CancerCompletedNCT00536861Phase 1
• Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins LymphomaCompletedNCT00536835Phase 1
• A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic CancerSuspendedNCT00536770Phase 2
• Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus BevacizumabCompletedNCT00536640Phase 2
• A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced CancerCompletedNCT00535522Phase 1
• SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00535379Phase 2
• BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00533585Phase 1
• Safety of ON 01910.Na in Patients With MyelodysplasiaCompletedNCT00533416Phase 1
• ZD6474 Alone and in Combination With Retinoic Acid in Pediatric NeuroblastomaTerminatedNCT00533169Phase 1
• Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal CancerCompletedNCT00532909Phase 1
• Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of TamoxifenTerminatedNCT00532454Phase 2
• An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian CancerStatus unknownNCT00532194Phase 3
• Sorafenib in Resected Non-small Cell Lung CarcinomaTerminatedNCT00532025Phase 2
• A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248CompletedNCT00531544Not applicable
• This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.CompletedNCT00531440Phase 3
• MAAM Study: Avastin and Macugen Versus Avastin Versus MacugenCompletedNCT00531336Phase 2
• This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of EverolimusCompletedNCT00531063Phase 3
• Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)CompletedNCT00530699Phase 1

← Protein Kinase Inhibitors overview